T2 Biosystems CS (TTOO)

$0.08 -0.06 (-41.49%)
Market Cap 4.09M
Revenue (ttm) 7.19M
Net Income (ttm) -50.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -696.52%
Debt to Equity Ratio 0.00
Volume 4,010,500
Avg Vol 1,494,488
Day's Range N/A - N/A
Shares Out 21.04M
Stochastic %K 5%
Beta 0.35
Analysts Hold
Price Target $5.00

Company Profile

T2 Biosystems, Inc. engages in the development and commercialization of medical diagnostic products for critical unmet needs in the healthcare. Its products include T2Dx instrument, T2Candida panel, and T2Bacteria panel. The company was incorporated in 2006 and is based in Lexington, Massachusetts.

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 781 761 4646
Address:
101 Hartwell Avenue, Lexington, United States
911AXX
911AXX Nov. 18 at 2:59 PM
$TTOO close down that crap criminals
0 · Reply
Luka_Brasi
Luka_Brasi Nov. 17 at 8:18 PM
$TTOO Are there any employees left. Or has Elvis left the building?
1 · Reply
Zefram
Zefram Nov. 17 at 3:22 PM
$TTOO you know you're desperate when you're asking microsoft edge questions.
0 · Reply
Zefram
Zefram Nov. 17 at 2:47 PM
$GNS $TTOO yup.. you can make a killing shorting these companies after reverse splits, but shorting them under $5.. let alone sub $1.. is just too much risk, even when the companies are clown fiestas. stupid bulls never understand that.
1 · Reply
BobbyJay55
BobbyJay55 Nov. 17 at 2:27 PM
$TTOO QIAGEN just liked this comment on LinkedIn? 🤔
2 · Reply
vincent_2025
vincent_2025 Nov. 17 at 10:19 AM
$TTOO Foor Clarification I asked Microsoft Edge CoPilot AI this question this morning: DD required. Is BARDA interested in a contract with T2 Biosystem's FDA cleared T2 Bio Threat Panels now that T2 Biosystems Intellectual property is offered for sale? Direct Answer: BARDA has previously funded and contracted with T2 Biosystems for the development of its T2Biothreat Panels, but there is no publicly available evidence that BARDA has expressed interest in acquiring or contracting for T2 Biosystems’ intellectual property now that it is being offered for sale.
0 · Reply
vincent_2025
vincent_2025 Nov. 17 at 4:26 AM
$TTOO Rapid bio threat Response project Vehicle nixed by Barda. https://www.rrpv.org/wp-content/uploads/2025/08/RRPV-RPP-25-06-DxR2-Phase-2_Amendment-1_Archive.pdf
1 · Reply
vincent_2025
vincent_2025 Nov. 17 at 3:06 AM
$TTOO Recent Funding: In 2025, BARDA exercised Contract Option 3, providing $3.7 million to advance the T2Biothreat panel. This confirms BARDA’s continued support.
1 · Reply
vincent_2025
vincent_2025 Nov. 17 at 3:05 AM
$TTOO Asked AI....does this mean T2 Biothreat panels are on hold with Barda? Direct answer: No — T2 Biosystems’ Biothreat panel program is not on hold. BARDA has continued funding through exercised contract options, and the new DxR2 solicitation is a broader initiative that complements, rather than replaces, T2’s ongoing work yahoo finance
0 · Reply
vincent_2025
vincent_2025 Nov. 17 at 3:04 AM
$TTOO https://everglade.com/bardas-dxr2-rpp-scaling-biothreat-diagnostic-readiness/
2 · Reply
Latest News on TTOO
No data available.
911AXX
911AXX Nov. 18 at 2:59 PM
$TTOO close down that crap criminals
0 · Reply
Luka_Brasi
Luka_Brasi Nov. 17 at 8:18 PM
$TTOO Are there any employees left. Or has Elvis left the building?
1 · Reply
Zefram
Zefram Nov. 17 at 3:22 PM
$TTOO you know you're desperate when you're asking microsoft edge questions.
0 · Reply
Zefram
Zefram Nov. 17 at 2:47 PM
$GNS $TTOO yup.. you can make a killing shorting these companies after reverse splits, but shorting them under $5.. let alone sub $1.. is just too much risk, even when the companies are clown fiestas. stupid bulls never understand that.
1 · Reply
BobbyJay55
BobbyJay55 Nov. 17 at 2:27 PM
$TTOO QIAGEN just liked this comment on LinkedIn? 🤔
2 · Reply
vincent_2025
vincent_2025 Nov. 17 at 10:19 AM
$TTOO Foor Clarification I asked Microsoft Edge CoPilot AI this question this morning: DD required. Is BARDA interested in a contract with T2 Biosystem's FDA cleared T2 Bio Threat Panels now that T2 Biosystems Intellectual property is offered for sale? Direct Answer: BARDA has previously funded and contracted with T2 Biosystems for the development of its T2Biothreat Panels, but there is no publicly available evidence that BARDA has expressed interest in acquiring or contracting for T2 Biosystems’ intellectual property now that it is being offered for sale.
0 · Reply
vincent_2025
vincent_2025 Nov. 17 at 4:26 AM
$TTOO Rapid bio threat Response project Vehicle nixed by Barda. https://www.rrpv.org/wp-content/uploads/2025/08/RRPV-RPP-25-06-DxR2-Phase-2_Amendment-1_Archive.pdf
1 · Reply
vincent_2025
vincent_2025 Nov. 17 at 3:06 AM
$TTOO Recent Funding: In 2025, BARDA exercised Contract Option 3, providing $3.7 million to advance the T2Biothreat panel. This confirms BARDA’s continued support.
1 · Reply
vincent_2025
vincent_2025 Nov. 17 at 3:05 AM
$TTOO Asked AI....does this mean T2 Biothreat panels are on hold with Barda? Direct answer: No — T2 Biosystems’ Biothreat panel program is not on hold. BARDA has continued funding through exercised contract options, and the new DxR2 solicitation is a broader initiative that complements, rather than replaces, T2’s ongoing work yahoo finance
0 · Reply
vincent_2025
vincent_2025 Nov. 17 at 3:04 AM
$TTOO https://everglade.com/bardas-dxr2-rpp-scaling-biothreat-diagnostic-readiness/
2 · Reply
vincent_2025
vincent_2025 Nov. 17 at 12:55 AM
$TTOO ai reply... OTC buyouts behave differently than NYSE/NASDAQ deals: prices may not rise immediately. Liquidity and credibility are critical — without active trading, the market doesn’t adjust quickly. Shareholders often wait until closing to see the premium realized in cash or stock.
1 · Reply
tcamp923
tcamp923 Nov. 17 at 12:17 AM
$TTOO microbial resistance is the biggest threat to humanity baring nuclear warfare
0 · Reply
tcamp923
tcamp923 Nov. 17 at 12:15 AM
$TTOO biotechnology is the next bubble Elizabeth Holmes destroyed investing in this sector but the pendulum always swings
0 · Reply
GatorYoYo
GatorYoYo Nov. 15 at 3:17 PM
$TTOO Sepsis was the core.... But ... Each of the other use cases and future use cases are all advancements in direct from blood diagnosis! Lyme disease Biothreat Anti microbial Resistance They are all different verticals and add rapid detection for important medical needs! Each provides value!
1 · Reply
vincent_2025
vincent_2025 Nov. 15 at 1:08 PM
$TTOO (AI response. Your DD required to confirm) regarding a question T2MR or NGS? 🤝 The Long-Term Outlook: Coexistence The most likely scenario is not T2 being replaced, but coexistence and complementary use: T2 (First Line): Used as the Stat/Urgent test in the ICU and ED to rapidly identify or rule out the most common, high-mortality pathogens (the "need-to-know-now" pathogens) in the first few hours. NGS (Second Line) Next Generation Sequencing: Used for comprehensive investigation in cases where the T2 test is negative, the patient is not responding to therapy, or the infection is suspected to be caused by a rare or unknown pathogen (the "nice-to-know-everything" pathogens). T2's sustained value will rest on its ability to leverage its unmatched speed in the acute setting and its patent protection on direct-from-blood detection to maintain its market position.
2 · Reply
vincent_2025
vincent_2025 Nov. 15 at 4:12 AM
$TTOO For chart enthusiast, and to stir up speculation, regarding company BO possibilities. See TMO 's 1 year chart... looks like a healthy Cup and Handle forming? Traditional finger crossing required :)
0 · Reply
charlieshim2015
charlieshim2015 Nov. 15 at 3:43 AM
$TTOO updated q3 10q so... M&A is still in play!!
1 · Reply
thedonutman
thedonutman Nov. 15 at 1:51 AM
$TTOO Interesting, apparantly bioMérieux was a past T2 patent opponent. See below: https://grok.com/share/c2hhcmQtMi1jb3B5_32591881-8142-4fe8-ac1e-b10c77a6ef78
1 · Reply
OTCnotWorking
OTCnotWorking Nov. 14 at 9:07 PM
$TTOO Hi Vincent - did you get any updates from Craig? Vincent - did you get any updates from Craig? Just trying to assess if there is any positive sentiment in your exchange with him.
2 · Reply
thombo1893
thombo1893 Nov. 14 at 5:54 PM
$TTOO Is not yet traded anymore in Germany :(
3 · Reply
vincent_2025
vincent_2025 Nov. 14 at 4:20 PM
$TTOO 11:19 am est OTC Market reporting volume at 1, ST chart noting not available.. slow start today.
1 · Reply
vincent_2025
vincent_2025 Nov. 13 at 11:14 PM
$TTOO another company posting an article on a new technology.. FDA cleared 30 minute test for sepsis.. don't know if it is a worry for t2 ? https://news.stanford.edu/stories/2025/02/a-better-faster-sepsis-test-that-can-save-lives#:~:text=Called%20TriVerity%E2%84%A2%2C%20The%20test%20evaluates%20a%20blood%20sample,test%27s%20foundation%20were%20identified%20by%20Khatri%20at%20Stanford.
4 · Reply